#AI

In September 2024, the Australian Government published the final report of the Health Technology Assessment (HTA) Policy and Methods Review. On the surface, it is a national reform document. In …

What Medicare’s DMHT Codes Signal for Digital Therapeutics Reimbursement and Why Healthcare Is Paying Attention Digital therapeutics reimbursement refers to how public and private healthcare systems pay for evidence-based software …

France 2030 medical device funding is a major public investment opportunity for teams developing implantable medical devices and next-generation surgical robotics. Managed via Bpifrance under the France 2030 investment plan, …

Belgium’s DRG debate is often framed as a shift toward “case-based payment.” That description is technically correct  but strategically misleading. In Belgium, DRGs are not a market-shaping instrument; they are …

Germany rarely announces a reimbursement change with fanfare. It tends to arrive indirectly through regulation, measurement, and administrative architecture. Sepsis is the latest example. From 1 January 2026, sepsis care …

Why “SaMD” Is the Wrong Place to Start On paper, Software as a Medical Device (SaMD) looks like progress.It gives artificial intelligence in healthcare a name, a definition, and a …

The HAS / CNEDiMTS route explained science, law, and real-world decisions France operates one of the most structured and evidence-based reimbursement systems for medical devices in Europe. Access is not …

The Promise and the Paradox The UK Government’s 10-Year Health Plan for England (2025–2035) presents itself as a blueprint for a modernised NHS—one that is digitally enabled, outcomes-measured, genomically informed, …

How Scientific Abstracts and Reimbursement Really Connect in MedTech and Digital Health This article explains how scientific abstracts and reimbursement are linked in the MedTech, IVD, and digital health sectors. …